Answers are grounded in this paper and cite their sources.
Lung cancer is a leading cause of cancer death, and late diagnosis is one of the most important reasons for the high mortality rate. microRNAs (miRNAs) are key players in gene regulation and therefore in tumorigenesis. As far as lung carcinogenesis is concerned, miRNAs open novel fields in biomarker research, in diagnosis, and in therapy. In this review we focus on miR-21 in lung cancer and especially on how miR-21 is involved 1) as a biomarker in response or resistance to therapy or 2) as a therapeutic target.
No takes yet. Share an insight, caveat, or question.
Lianidou et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: